Limited preclinical evidence has been generated in BC models harboring RET rearrangements with the available evidence indicating that cabozantinib reduces the proliferative potential of breast cancer cells displaying the NCOA4-RET fusion (52). Here, NCOA4 is linked to breast cancer.